Trimurthi has received an approval to invest the funds in its Wholly Owned Subsidiary (WOS) amounting to Rs 75 lakh (7,50,000 Shares of Rs 10 each). The board of directors at their meeting held on January 8, 2018, approved for the same.
The company is engaged in the manufacturing, distribution, marketing and trading of pharmaceutical products. The company’s range of products include antibiotics, anti ulcer, anti inflammatory, antitussive/expectorant, cardiovascular, anti fungal, anti retroviral drugs, syrups and protein powder.
